Nine-Month Interim Report (Q3) 2026 (Unaudited)
| Growth | Growth | |||||
| In DKKm | Q3 2026 | l.c. | r.c. | 9M 2026 | l.c. | r.c. |
| Revenue | 1,764 | 15% | 15% | 5,330 | 17% | 16% |
| EBIT | 469 | 9% | 11% | 1,484 | 16% | 17% |
| EBIT margin – % | 27% | 28% | ||||
| l.c.: local currency; r.c.: reported currency |
Allergy+ strategy highlights
- ALK and its Chinese partner GenSci expects to file for regulatory approval of the house dust mite tablet ACARIZAX®in China in H1 2027, based on the recent successful outcome of a phase 3 clinical trial. neffy® nasal adrenaline spray (2 mg) launched in 14 markets at the end of September. The recent launch in Canada and the 1 mg launch for young children in Germany are progressing well. ALK has entered into a partnership with Zuellig Pharma for select Southeast Asian markets, under which Zuellig will sub-license neffy® from ALK. ALK has expanded its partnership with Catalent to secure long-term access to the Zydis® tablet technology formulation and increase annual tablet manufacturing capacity to 1.1 billion from the early 2030s. ALK has submitted a clinical trial application to the US Food and Drug Administration (FDA) and is currently awaiting feedback from the authorities on the peanut allergy tablet phase 3 development plans before initiating the trial.
2026 full-year outlook confirmed
The full-year financial outlook was upgraded on 7 October 2026 (reference is made to Company Release 16/2026), reflecting a strong growth momentum in tablet sales across regions. This outlook has been confirmed.
- Revenue is expected to grow by 16-17% in local currencies, based on growth across all sales regions and product lines with tablets as the key driver of growth. The EBIT margin is expected at around 27%, mainly reflecting operating leverage from the revenue growth.
Commenting on the Q3 results, CEO Peter Halling said:“ALK's 35% tablet growth in Q3 reflects the strength of our strategy, and paediatric use is increasingly contributing to the growth. We are very pleased that the phase 3 trial with ACARIZAX® in China met its primary objective opening up a new important opportunity, and the expanded partnership with Catalent strengthens our long-term tablet supply. Together with the upgraded outlook, this reinforces our confidence in our ability to reach more patients with evidence-based allergy and anaphylaxis solutions."
Hørsholm, 17 November 2026
ALK-Abelló A/S
For further information, contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
ALK is hosting a conference call for analysts and investors today at 3.30 p.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on where the relevant presentation will be available shortly before the call begins.
To register for the conference call, please use this link and follow the registration instructions. You will receive an email from... with dial-in details, including a passcode and a pin code. Please make sure to whitelist... and/or check your spam filter. We advise you to register well in advance and to call in before 3.25 p.m. (CET).
Attachment
-
Company release_19_26UK_171126_Q3 26 interim report

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment